menu
    • menu
    [{"orgOrder":0,"company":"Akouos","sponsor":"Pivotal bioVenture Partners","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"AK-OTOF","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0.11,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0.11,"dosageForm":"","sponsorNew":"Akouos \/ Pivotal bioVenture Partners","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Pivotal bioVenture Partners"},{"orgOrder":0,"company":"Akouos","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"AK-OTOF","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0.10000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Akouos \/ BofA Securities","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ BofA Securities"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"OTOF-GT","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sensorion \/ Not Applicable"},{"orgOrder":0,"company":"Akouos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"AK-OTOF","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear","sponsorNew":"Akouos \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Not Applicable"},{"orgOrder":0,"company":"Akouos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"AK-OTOF","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear","sponsorNew":"Akouos \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Not Applicable"},{"orgOrder":0,"company":"Akouos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AK-OTOF","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"","sponsorNew":"Akouos \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Not Applicable"},{"orgOrder":0,"company":"Akouos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AK-OTOF","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akouos \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Not Applicable"},{"orgOrder":0,"company":"Akouos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AK-OTOF","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akouos \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Not Applicable"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Otoferlin","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"","sponsorNew":"Decibel Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Decibel Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Myrtelle","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"AAV-based TMPRSS3 Gene Therapy","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"","sponsorNew":"Forge Biologics \/ Myrtelle","highestDevelopmentStatusID":"5","companyTruncated":"Forge Biologics \/ Myrtelle"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"OTOF-GT","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sensorion \/ Not Applicable"},{"orgOrder":0,"company":"Akouos","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"AK-OTOF","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0.48999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0.48999999999999999,"dosageForm":"Injection","sponsorNew":"Akouos \/ Eli Lilly","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Eli Lilly"},{"orgOrder":0,"company":"Akouos","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"AK-OTOF","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":1.1000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0.48999999999999999,"dosageForm":"Injection","sponsorNew":"Akouos \/ Eli Lilly","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Eli Lilly"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SENS-501","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sensorion \/ Not Applicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"OTOF-GT","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sensorion \/ Not Applicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SENS-501","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sensorion \/ Not Applicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"OTOF-GT","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sensorion","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Sensorion \/ Redmile Group","highestDevelopmentStatusID":"5","companyTruncated":"Sensorion \/ Redmile Group"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"OTOF-GT","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sensorion \/ Not Applicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"OTOF-GT","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sensorion","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Sensorion \/ Redmile Group","highestDevelopmentStatusID":"5","companyTruncated":"Sensorion \/ Redmile Group"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ebselen","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"","sponsorNew":"Sound Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sound Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sound Pharmaceuticals

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Sound Pharmaceuticals

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ebselen

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sound Pharmaceuticals’ IND Involving Cochlear Implantation Allowed by the FDA

                            Details : SPI-1005 (ebselen) is a novel anti-inflammatory Glutathione Peroxidase mimetic, an enzyme critical to hearing and balance. It is being tested for residual hearing loss reduction during and after CI.

                            Brand Name : SPI-1005

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 20, 2024

                            Lead Product(s) : Ebselen

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sensorion

                            France arrow
                            Fi Europe 2024
                            Not Confirmed

                            Sensorion

                            France arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OTOF-GT

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : IND Enabling

                            Sponsor : Redmile Group

                            Deal Size : $16.2 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Sensorion Announces a €15 Million Financing, Extending Cash Runway Until the End of 2025

                            Details : The financing aims to fund the clinical development of SENS-501 (OTOF-GT) small molecule programs for the treatment and prevention of hearing loss disorders.

                            Brand Name : SENS-501

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 08, 2024

                            Lead Product(s) : OTOF-GT

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : IND Enabling

                            Sponsor : Redmile Group

                            Deal Size : $16.2 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sensorion

                            France arrow
                            Fi Europe 2024
                            Not Confirmed

                            Sensorion

                            France arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OTOF-GT

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : IND Enabling

                            Sponsor : Redmile Group

                            Deal Size : $54.4 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Sensorion Announces Financing With Participation From US And European Healthcare Investors

                            Details : Through financing, Sensorion will prioritize the development of SENS-501 ( OTOF-GT), which aims to restore hearing in individuals with Otoferlin deficiency, a prevalent form of congenital deafness.

                            Brand Name : SENS-501

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 09, 2024

                            Lead Product(s) : OTOF-GT

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : IND Enabling

                            Sponsor : Redmile Group

                            Deal Size : $54.4 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sensorion

                            France arrow
                            Fi Europe 2024
                            Not Confirmed

                            Sensorion

                            France arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OTOF-GT

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sensorion Receives Approval to Begin Phase 1/2 Trial of SENS-501 in Europe

                            Details : SENS-501 (OTOF-GT) is a dual vector AAV gene therapy aiming to restore hearing in patients with otoferlin protein mutations causing severe to profound hearing loss.

                            Brand Name : SENS-501

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 19, 2024

                            Lead Product(s) : OTOF-GT

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sensorion

                            France arrow
                            Fi Europe 2024
                            Not Confirmed

                            Sensorion

                            France arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SENS-501

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe

                            Details : OTOF-GT is a dual AAV vector gene therapy development program aims to restore hearing in patients with mutations in OTOF who suffer from severe to profound sensorineural prelingual non syndromic hearing loss.

                            Brand Name : OTOF-GT

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            July 19, 2023

                            Lead Product(s) : SENS-501

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sensorion

                            France arrow
                            Fi Europe 2024
                            Not Confirmed

                            Sensorion

                            France arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OTOF-GT

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sensorion Submits Clinical Trial Application for Lead Gene Therapy Candidate OTOF-GT in The UK

                            Details : OTOF-GT is a dual AAV vector gene therapy development program aims to restore hearing in patients with mutations in OTOF who suffer from severe to profound sensorineural prelingual non syndromic hearing loss.

                            Brand Name : OTOF-GT

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            July 07, 2023

                            Lead Product(s) : OTOF-GT

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Decibel Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Decibel Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DB-OTO

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Pro...

                            Details : DB-OTO is a gene therapy product candidate designed to provide durable restoration (selectively express functional OTOF in the inner hair cells) of hearing to individuals born with profound hearing loss due to mutation of the OTOF gene.

                            Brand Name : DB-OTO

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 24, 2023

                            Lead Product(s) : DB-OTO

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Akouos

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Akouos

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AK-OTOF

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : IND Enabling

                            Sponsor : Eli Lilly

                            Deal Size : $1,097.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases

                            Details : AK-OTOF is a dual adeno-associated viral (AAV) vector-based gene therapy intended to treat patients with OTOF-mediated hearing loss by delivering transgenes encoding OTOF to the inner hair cells (IHCs) of the cochlea.

                            Brand Name : AK-OTOF

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $1,097.0 million

                            December 01, 2022

                            Lead Product(s) : AK-OTOF

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : IND Enabling

                            Sponsor : Eli Lilly

                            Deal Size : $1,097.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sensorion

                            France arrow
                            Fi Europe 2024
                            Not Confirmed

                            Sensorion

                            France arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : R-Azasetron Besylate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sensorion Announces Approval to Initiate Amended Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cispl...

                            Details : SENS-401 (arazasetron), is an orally available small molecule that aims to protect and preserve inner ear tissue from damage responsible of progressive or sequelae hearing impairment.

                            Brand Name : SENS-401

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 24, 2022

                            Lead Product(s) : R-Azasetron Besylate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Akouos

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Akouos

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AK-OTOF

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : IND Enabling

                            Sponsor : Eli Lilly

                            Deal Size : $487.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss

                            Details : Proposed acquisition will accelerate gene therapies that aim to restore, improve, and preserve hearing for patients living with disabling hearing loss worldwide including lead product, AK-OTOF, a treatment of hearing loss due to mutations in the otoferli...

                            Brand Name : AK-OTOF

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $487.0 million

                            October 18, 2022

                            Lead Product(s) : AK-OTOF

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : IND Enabling

                            Sponsor : Eli Lilly

                            Deal Size : $487.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth